Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  World Journal of Gastroenterology

• Publication date

  2007-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3748/WJG.V13.I8.1292PMID 17451219PMCID PMC4147013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The clinical and physiological spectrum of interferon‐alpha induced thyroiditis: Toward a new classification

  2006cited by this paper
• Prognostic significance of autoimmunity during treatment of melanoma with interferon.

  2006cited by this paper
• Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.

  2006cited by this paper
• [Chronic hepatitis C with early complication of Grave's disease during the treatment of pegylated interferon alpha-2a].

  2005cited by this paper
• Late Development of Diabetes mellitus after Interferon-Alfa and Ribavirin Therapy for Chronic Hepatitis C: A Case Report

  2005cited by this paper
• Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity.

  2004cited by this paper
• [Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].

  2004cited by this paper
• [Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha].

  2004cited by this paper
• Massive increase of insulin resistance in a patient with chronic hepatitis C after treatment with interferon.

  2004cited by this paper
• Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C.

  2003cited by this paper
• A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy.

  2003cited by this paper
• Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C.

  2003cited by this paper
• Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy

  2003influential reference
• Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy.

  2003influential reference
• Diabetes mellitus during interferon therapy for chronic viral hepatitis.

  2002cited by this paper
• Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C

  2001cited by this paper
• Fulminant autoimmune Type 1 diabetes during interferon‐alpha therapy: a case of Th1‐mediated disease?

  2001influential reference
• Abrupt onset of diabetes during interferon‐alpha therapy in patients with chronic hepatitis C

  2001cited by this paper
• Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon‐α

  2000cited by this paper
• Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C.

  1999cited by this paper
• [Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C].

  1999cited by this paper
• Effects of long-term interferon-α treatment on glucose tolerance in patients with chronic hepatitis C

  1999cited by this paper
• Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis.

  1998cited by this paper
• Interferon induces insulin resistance in patients with chronic active hepatitis C.

  1998cited by this paper
• Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

  1997cited by this paper
• Side effects of high-dose interferon therapy for chronic hepatitis C.

  1996influential reference
• A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

  1996influential reference
• Interferon-alpha and IDDM: comment

  1996cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• [Glucose intolerance during interferon therapy in patients with chronic hepatitis type C].

  1994cited by this paper
• Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis.

  1992cited by this paper
• Effect of Interferon on Glucose Tolerance and Insulin Sensitivity

  1989cited by this paper

• Dietary Influence on Drug Efficacy: A Comprehensive Review of Ketogenic Diet–Pharmacotherapy Interactions

  2024cites this paper
• Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto’s thyroiditis: a case report

  2022cites this paper
• A systematic review and meta-analysis of endocrine-related adverse events associated with interferon

  2022cites this paper
• Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review.

  2022cites this paper
• Methamphetamine use and the risk of diabetic ketoacidosis

  2021cites this paper
• Interferon therapy in hepatitis C leading to chronic type 1 diabetes.

  2015cites this paper
• Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations

  2013cites this paper
• Type 1 diabetes mellitus in patient with hepatitis c treated with interferon á. First case in Cuba

  2013cites this paper
• Patients with chronic hepatitis type C and interferon-alpha-induced hyperthyroidism in two-years clinical follow-up.

  2013cites this paper
• Underlying pathways for interferon risk to type II diabetes mellitus.

  2013cites this paper
• Hepatitis C virus and type 1 diabetes.

  2013cites this paper
• Diabetes mellitus tipo 1 en una paciente con hepatitis c durante el tratamiento con interferón alfa. Primer caso comunicado en Cuba

  2013cites this paper
• A rare case of Interferon-alpha-Induced Hyperthyroidism in patients with a chronic hepatitis C with granulocytopenia and transaminasemia treated successfully with radioiodine.

  2012cites this paper
• Chronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy.

  2012cites this paper
• Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus.

  2012cites this paper
• Organ-Specific Autoimmunity in HCV-Positive Patients

  2012cites this paper
• Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review

  2011cites this paper
• [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].

  2010cites this paper
• Type 1 Diabetes Caused by Interferon α-2α in Polycythemia Vera Therapy

  2010cites this paper
• Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

  2010cites this paper
• Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.

  2009cites this paper
• Bibliography. Current world literature. Diabetes and the endocrine pancreas.

  2008cites this paper
• Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.

  2008cites this paper
• IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C. Case report.

  2008cites this paper
• [Diabetes mellitus during interferon therapy].

  2008cites this paper
• Diabetes mellitus en relacin con tratamiento con interfern

  2008cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2007cites this paper
• Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management

  2007cites this paper
• [Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction].

  2007cites this paper
• Diabetic ketoacidosis.

  2005cites this paper